SPP-037
SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC50: 3.59 μM) . SPP-037 exhibits anti-MDA-MB-231 cell migration activity by inhibiting integrin α2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used in breast cancer research[1].
Product Specifications
UNSPSC
12352211
Target
Endogenous Metabolite; FAK
Related Pathways
Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
[H][C@]12CC[C@@]3([C@H](CC[C@]3([C@@]1(CC[C@@]4(C[C@@H](CC[C@]24C)OC([C@@H](NS(=O)(C5=CC=C(C6=NON=C56)Cl)=O)CC(O)=O)=O)[H])[H])[H])[C@@H](CCCCC(O)=O)C)C
Molecular Formula
C36H50ClN3O9S
Molecular Weight
736.31
References & Citations
[1]Perez SJLP, et al. Harnessing the bishomolithocholic acid scaffold for selective sialyltransferase inhibition: A targeted approach to suppress breast cancer metastasis. Eur J Med Chem. 2025 Aug 5;292:117674.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-172888/
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PH0169M80 100 µg
SARS-CoV-2 Nucleocapsid (P13L, R203K, G204R, G237C) Protein (His Tag)
Ask
View Details